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The in vitro activity of a host defense peptidomimetic
(HDM-4) was investigated. The compound exhibited
an antimicrobial activity profile against a range of
Gram-negative bacteria. HDM-4 permeabilized the
outer membrane and partly depolarized the inner
membrane at its minimal inhibitory concentration
(MIC). Moreover, it was demonstrated that HDM-4
was distributed widely in the bacterial cell at lethal
concentrations, and that it could bind to DNA. It
was confirmed that the multimodal action of HDM-4
resulted in it being less likely to lead to resistance
development as compared to single-target antibi-
otics. HDM-4 exhibited multispecies anti-biofilm
activity at sub-MIC levels. Furthermore, HDM-4
modulated the immune response by inducing the
release of the chemoattractants interleukin-8 (IL-8),
monocyte chemotactic protein-1 (MCP-1), and
MCP-3 from human peripheral blood mononuclear
cells. In addition, the compound suppressed lipo-
polysaccharide-mediated inflammation by reducing
the release of the pro-inflammatory cytokines IL-6
and tumor necrosis factor-a.
INTRODUCTION
Reports of the emergence of resistance development among
pathogenic bacterial strains continue to increase. Infectious dis-
eases will become increasingly less treatable with conventional
antibiotics and thus new clinical strategies are urgently needed
(Theuretzbacher, 2013). At the same time, there is a declining
effort from pharmaceutical companies in pursuing the develop-
ment of new classes of anti-infective agents, and few new anti-
bacterial agents are being approved in the United States
(Boucher et al., 2009; Jabes, 2011). Thus, to solve this persistent
health problem, the research and development of new anti-infec-
tive agents constitutes an important task for academic institu-
tions. Antimicrobial host defense peptides (HDPs) have for
many years been considered lead compounds for novel antibi-
otics (Brogden, 2005; Hancock and Sahl, 2006; Mookherjee
and Hancock, 2007). However, after 30 years of efforts, synthetic
antimicrobial peptides have had very limited success. General1286 Chemistry & Biology 20, 1286–1295, October 24, 2013 ª2013 Eproblems encountered are typically toxicity, cost of raw mate-
rials, and susceptibility toward enzymatic degradation (Fjell
et al., 2012; Hancock and Sahl, 2006).
In this study, we characterized the in vitro activity of a proteo-
lytically stable simple host defense peptidomimetic (HDM-4)
with low toxicity toward mammalian cells. We showed that
HDM-4 counteracted Gram-negative pathogens in a multifunc-
tional manner through membrane disruption and DNA binding.
Additionally, HDM-4 promoted immunomodulatory anti-infective
functions by inducing chemokines in immune cells and inhibiting
lipopolysaccharide (LPS)-induced pro-inflammatory responses.RESULTS
Spectrum of Activity and Killing Kinetics
We previously reported that HDM-4 exhibits low toxicity against
red blood cells andHeLa cells aswell as high antibacterial activity
against E. coli multidrug-resistant strains including ESBL and
NDM-1producers (Jahnsenetal., 2012). Theactivity againstaddi-
tional Gram-negative bacteria was investigated (Table 1). Several
HDPs reported in the literature were included in the screen: poly-
myxin B (Storm et al., 1977), a polypeptide isolated from Bacillus
polymyxus; IDR-1018 (Wieczorek et al., 2010), a synthetic short
cationic immunomodulating peptide with weak direct antibacte-
rial activity; CRAMP (Gallo et al., 1997), a natural cathelin-related
murine antimicrobial peptide; and bovine bactenecin derivatives
Bac2A and W3 (Hilpert et al., 2005; Wieczorek et al., 2010).
HDM-4 exhibited broad-spectrum activity at levels (minimum
inhibitory concentration [MIC] % 10 mM) comparable to many
of the known HDPs (Table 1). In particular, the growth of E. coli
and K. pneumoniae was inhibited at low concentrations. The
killing kinetics of E. coli exposed to HDM-4 were compared to
those observed for several clinically applied antibiotics, and
HDM-4 was investigated at various concentrations (Figure 1).
At 4-fold the MIC, HDM-4 killed E. colimore rapidly than other
antibiotics commonly used in the clinic (Figure 1). Antimicrobial
HDPs are proposed to exert their direct bacterial killing by a
multimodal mechanism of action involving combinations of
disruption of membrane barrier function, antagonism of biosyn-
thetic processes that involve cytoplasmic membrane-associ-
ated enzymes, internalization, and action on cytosolic targets
(Fjell et al., 2012; Hale and Hancock, 2007). Thus, upon reaching
a threshold concentration, peptides accumulated at the lipid
bilayer can rapidly cause cell death as previously shown for poly-
myxin B (HsuChen and Feingold, 1973). Notably, HDM-4 actedlsevier Ltd All rights reserved
Table 1. Antibacterial Activity of HDM-4
Compound/Strain
MIC [mg/ml] (mM)
E. coli P. aeruginosa S. enterica Typhimurium A. baumannii K. pneumoniae
HDM-4 4 (1.3) 32 (10) 32 (10) 32 (10) 0.5 (0.2)
Polymyxin B 2 (1.4) 1 (0.7) 0.5 (0.4) 16 (11) 2 (1.4)
IDR-1018 32 (15) >64 (>30) 16 (7.6) 16 (7.6) 2 (0.9)
CRAMP 32 (8.4) >64 (>17) >64 (>17) >64 (>17) 32 (8.4)
Bac2A 32 (23) >64 (>45) >64 (>45) >64 (>45) 4 (2.8)
W3 16 (10) >64 (>41) 32 (>21) 16 (10) 2 (1.3)
The MIC of HDM-4 against several clinically important Gram-negative pathogens.
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tions, the killing took place within hours after an initial lag phase.
These observations suggest that alternative more ‘‘slow-acting’’
mechanisms other than membrane disruption are involved for
HDM-4, most likely implicating inhibition of essential metabolic
functions including DNA, RNA, or protein synthesis (Hale and
Hancock, 2007).
Mode of Action
To further elucidate the antibacterial mode of action, the effects
of HDM-4 on E. coli were investigated using a range of micro-
scopic and spectroscopic methods as well as functional assays
(Figure 2).
Effects on the outer membrane of E. coli were demonstrated
with field emission scanning-electron microscopy (Figure 2B).
At the MIC, the micrographs clearly showed membrane damage
including blebs, especially localized at the end of the bacterial
rod. The disruptive effects were more pronounced with
increased concentration, which corresponded well to the con-
centration-dependent killing rate observed in Figure 1B. General
morphologic changes were observed at all concentrations, but
extensive leakage of intracellular material was only detected at
higher concentrations (32 mg/ml; 83MIC), and even at this con-
centration cells generally maintained their shapes, indicating a
lack of lysis, and thereby corroborating the assumption that
intracellular targets may be involved at the MIC. Outer mem-
brane permeabilization of E. coli O157:H7 was measured with
the 1-N-phenylnapthylamine (NPN) assay (Loh et al., 1984)
with polymyxin B as a positive control (Figure 2C). At the MIC
(4 mg/ml), HDM-4 caused 75% permeabilization relative to
excess polymyxin B. Inner membrane depolarization was then
measured using the diSC3-5 assay (Wu et al., 1999) with the
membrane-active peptide melittin as a positive control (Fig-
ure 2D). To eliminate interference from the outer membrane in
uptake of diSC3-5, an E. coli (DC2) strain with a weakened outer
membrane was used in this assay. The MIC toward this strain
was 2-fold higher than that against the O157:H7 strain, consis-
tent with the possibility that outer membrane permeabilization
in E. coli was not rate-limiting for HDM-4 action. A strong con-
centration-dependent activity was observed, but the effect
was most pronounced at sub-MIC levels. Nevertheless, at the
MIC (8 mg/ml) only 42% depolarization relative to that of excess
melittin was observed. Interestingly, further addition of HDM-4
resulted in a more moderate increase in depolarization, while
complete depolarization required 103 MIC (40 mg/ml). These
data were thus consistent with the suggestion that mechanismsChemistry & Biology 20, 1286–1other than inner membrane disruption were involved in killing at
the MIC.
To investigate a putative intracellular mechanism for HDM-4, a
TAMRA-labeled derivative (Figure 2A) was synthesized. To
examine the potential impact of the altered physicochemical
properties of the labeled compound on its activity, the bacterial
killing ability of TAMRA-HDM-4 was compared to that of native
HDM-4 (Figure 2E). Labeling the compound resulted in a 2-fold
increase in MIC as compared to the original compound. An ex-
amination of the killing kinetics (adjusted for the difference in
MIC) showed comparable time-kill curves during treatment
with 83 MIC. The distribution of TAMRA-HDM-4 in bacterial
cells after 30 min was depicted with confocal imaging (Fig-
ure 2F). At 0.53 MIC (4 mg/ml) TAMRA-HDM-4 localized only
in the membrane, and mainly at the ends of the bacterial rods,
whereas general distribution into most parts of the cells was
observed at the MIC (i.e., 8 mg/ml). At 43 MIC (32 mg/ml), the
membranes were extensively perturbed, and TAMRA-HDM-4
was present also in the area surrounding the bacterial cells. To
investigate the capability of HDM-4 for binding intracellular com-
ponents such as DNA, a gel-retardation assay (Haney et al.,
2013) was performed (Figure 2G). Inhibition of plasmid migration
in the agarose gel was detectable at a HDM-4:plasmid weight
ratio of 2:1, with complete inhibition observed at ratios greater
than 3:1.
Resistance Development against HDM-4 in E. coli
An evaluation of the ability of HDM-4 to induce resistance devel-
opment in E. coli upon long-term exposure was carried out
(Figure 3).
Because HDM-4 appeared to act via multiple non-specific tar-
gets, it was expected that resistance upon repetitive sub-MIC
treatment would be less likely to occur for HDM-4 as compared
to conventional antibiotics having a single specific target. The
investigation indeed demonstrated that E. coli, when exposed
to sub-lethal concentrations for 20 cycles, exhibited a higher
relative susceptibility to HDM-4 than to representatives of the
major antibiotic classes including aminoglycosides (gentamicin),
carbapenems (imipenem), cephalosporins (cefotaxime), and flu-
oroquinolones (ciprofloxacin). Only polymyxin B demonstrated a
lower tendency for resistance development because the MIC
remained constant after 20 cycles. At least an 8-fold increase
in the MIC was obtained for the tested conventional antibiotics,
whereas only a 2-fold increase was observed for HDM-4. The
resistance properties were not caused by adaptive resistance,
as the treated bacteria were grown for additional two cycles295, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1287












































Figure 1. Killing Kinetics
(A) Time-kill study of E. coli O157:H7 exposed to various antibacterials. Cul-
tures in log phase at 3.5 3 106 to 5.5 3 106 CFU/ml were challenged with 4 3
MIC; all numbers recorded as 102 had%100 CFU/ml.
(B) Time-kill study of E. coli O157:H7 exposed to HDM-4 at various concen-
trations relative to the MIC of 4 mg/ml. The experiment was performed three
times and one representative curve for each concentration is shown.
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of the population was still present.
Broad-Spectrum Antibiofilm Activity
It was recently demonstrated that small synthetic cationic pep-
tides are able to disrupt bacterial biofilm formation (de la
Fuente-Nu´n˜ez et al., 2012). A screening for inhibition of biofilm
formation by different Gram-negative bacteria was performed
(Figure 4A). The planktonic MICs in biofilm medium were in two
cases slightly different as compared to those obtained in the
standard MIC assay medium, being 16–64 mg/ml. Interestingly,
inhibition of biofilm formation at sub-MIC concentrations was
found for all investigated bacteria. In particular, biofilm growth
for P. aeruginosa and A. baumannii was diminished significantly
even at a concentration 8-fold lower than theMIC. For all strains,
the biomass was reduced by > 90% at 16 mg/ml (i.e., at 0.125–
0.53 planktonic cell MIC).
More details about the antibiofilm activity were obtained by
subjecting P. aeruginosa to flow cell-based biofilm investigations
(Figure 4B). Bacteria were allowed to adhere to a glass surface
for 2 hr. Subsequently, a continuous flow of medium containing
0.1253 MIC of HDM-4 was applied for 6 days. The biofilm was
live/dead stained and visualized with confocal microscopy. In
the untreated control, a ‘‘lawn-like’’ biofilm with well-defined
microcolony structures was seen, and electron microscopy im-
aging showed a smooth biofilm surface comprising many cells
with healthy morphology. In contrast, the treated sample ex-
hibited a majority of dead cells as revealed by staining with
both the general stain Syto-9 Green and the normally imperme-
ant stain propidium iodide. A ‘‘lawn-like’’ biofilm structure was1288 Chemistry & Biology 20, 1286–1295, October 24, 2013 ª2013 Eabsent, but well-defined microcolonies were readily detected,
albeit that the majority of cells were dead, especially at the
core of the biofilm colonies. Electron microscopy revealed
smooth bacterial cell surfaces and a relatively high abundance
of extracellular polymeric matrix.
Immune Response Modulation
There is evidence that certain host defense peptides (e.g., the
human cathelicidin LL-37) also participate in the innate immune
response to infections by stimulating chemokine release,
thereby mobilizing the immune system (Scott et al., 2002). Syn-
thetic peptides have been designed to mimic and accentuate
this activity (Scott et al., 2007). Human peripheral bloodmononu-
clear cells (PBMCs) were stimulated with HDM-4 to investigate
its ability to induce production of the neutrophil chemokine inter-
leukin 8 (IL-8; CXCL8) as well as the monocyte chemotactic
proteins MCP-1 and MCP-3 (also termed CCL2 and CCL7,
respectively, because they belong to the subfamily of CC che-
mokines). The strongly immunomodulatory peptide IDR-1018
(Wieczorek et al., 2010) was included as a positive control. The
cytotoxic effects of IDR-1018 and HDM-4 were investigated
with the lactate dehydrogenase (LDH) assay (Decker and Loh-
mann-Matthes, 1988) at relevant concentrations prior to chemo-
kine investigations. At 20 mg/ml, HDM-4 and IDR-1018 demon-
strated 7.5 ± 6.7% and 2.2 ± 4.7% LDH release, respectively.
At 50 mg/ml, the release was 10.3 ± 7.8%and0%, respectively.
As expected, a strong induction of chemokines was observed
for IDR-1018 at both concentrations tested (Figure 5A). No signif-
icant chemokine induction was detected for HDM-4 at 20 mg/ml,
however, when stimulating with 50 mg/ml, significant induction of
all chemokines to levels comparable to those seen for low-dose
IDR-1018 treatment was observed.
In response to the bacterial outer-membrane component LPS,
the monocytes of infected hosts excrete excessive amounts of
pro-inflammatorymediators, like the cytokines IL-6 and tumor ne-
crosis factor-a (TNF-a), that can be harmful and lead to a poten-
tially lethal systemic inflammatory response syndrome (Davies
and Hagen, 1997). LL-37 and certain synthetic peptides are
known to inhibit the LPS-induced release of pro-inflammatory cy-
tokines through a complex mechanism (Mookherjee et al., 2006;
Turner-Brannen et al., 2011). In addition, it has been shown that
short cationic peptides exert an inhibitory effect on the LPS-
induced inflammatory response by blocking the interaction be-
tween LPSand LPS-binding protein (Scott et al., 2000). The ability
of HDM-4 to inhibit the LPS-mediated pro-inflammatory response
was investigated (Figure 5B), and its LPS-binding properties were
determined (Figure 5C). Because IDR-1018 has been previously
shown to strongly inhibit the pro-inflammatory response (Wiec-
zorek et al., 2010), it was included as a positive control in addition
to polymyxin B. Treatment with the compounds alone did not
induce significant levels of IL-6 or TNF-a (data not shown). Addi-
tion of HDM-4 together with LPS inhibited the release of TNF-a
and IL-6 from PBMCs. For TNF-a, both HDM-4 and IDR-1018
completely abolished the cytokine signal, whereas for IL-6, low
levels of cytokine could still be detected, with HDM-4 being
slightly more efficient than IDR-1018. Both compounds exhibited
concentration-dependent fluorophore displacement from LPS,
with HDM-4 being slightly more active. Polymyxin B gave rise to
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Figure 2. Investigations of the Antibacterial Mode of Action of HDM-4
(A) Structure of native HDM-4 (R1) and TAMRA-labeled HDM-4 (R2).
(B) Scanning-electronmicrographs of E. coliO157:H7 exposed to HDM-4 at various concentrations relative to theMIC of 4 mg/ml. Cultures in log phase (3.0–4.03
107 CFU/ml) were treated for 30 min prior to fixation and sample preparation.
(C) Outer membrane damage of E. coli O157:H7 at low HDM-4 concentrations. At time zero, test compounds were added to the sample. Excess polymyxin B
(6.4 mg/ml) demonstrated complete permeabilization. At the MIC (4 mg/ml), 75% permeabilization relative to polymyxin B was observed. The experiment was
performed three times and one representative curve for each concentration is shown.
(D) Concentration-dependent cytoplasmic membrane depolarization of E. coli (DC2). The results are presented as mean % depolarization ± SD of three inde-
pendent experiments assessed relative to that of excess melittin (20 mM = 57 mg/ml). The MIC of HDM-4 against E. coli (DC2) was 8 mg/ml and led to a 42%
depolarization. Data are represented as mean ± SEM.
(E) Time-kill kinetics for E. coli (O157:H7) exposed to native HDM-4 and TAMRA-labeled HDM-4 (MIC = 8 mg/ml). Cultures in log phase at 3.5–5.5 3 106 CFU/ml
were challengedwith 43MIC; all counts% 100CFU/ml are depicted as 102 CFU/ml. The experiment was performed three times and one representative curve for
each concentration is shown.
(F)ConfocalmicrographsofE.coli (O157:H7)afterexposure toTAMRA-labeledHDM-4 (false-coloredmagenta) atvariousconcentrationsandcounterstainingwith the
DNAfluorescentstain40,6-diamidino-2-phenylindole (DAPI) (false-coloredgreen).Cultures in logphase (3.93107CFU/mL)were treated for30minprior tofixationand
sample preparation. The scale bars represent 1 mm. An untreated control was examined to confirm that no background fluorescence was present (data not shown).
(G) Inhibition of plasmid pUCP19 DNA migration on a 1% agarose gel at different HDM-4:plasmid weight ratios.
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Figure 3. Resistance Development Induced by Antibacterial Agents
Development of resistance in E. coli (O157:H7) after 20 consecutive passages
continuously treated with antibiotics or HDM-4 at sublethal levels. The relative
MIC is the ratio of the MIC obtained for a given subculture exposed for 20
passages relative to that observed during the first passage.
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Multidrug-resistant bacteria are becoming increasingly preva-
lent. As recently as a decade ago, most of these organisms
posed little health risk, as they could be treated with one or
more conventional antibiotics. Today, the situation has changed
dramatically, and, in particular, Gram-negative bacteria like E.
coli, Pseudomonas, Klebsiella, and Acinetobacter spp. are
considered severe threats to public health (Oteo et al., 2010).
In the present work, we have extensively characterized the anti-
microbial activity andmechanism of action of HDM-4, a nontoxic
peptidomimetic with potent broad-spectrum antibacterial activ-
ity against a range of Gram-negative species. We propose that
HDM-4 may combat bacterial infections in a multifunctional
manner and thus, bacterial killing takes place as the result of
an overall mode of action involving cell membrane perturbation
and binding to intracellular components such as bacterial DNA.
In addition, the immunomodulatory properties of HDM-4 could
lead to enhanced bacterial clearance by the cells of the host im-
mune system, resulting in amultipronged attack against invading
pathogens. HDPs have been called ‘‘dirty drugs’’ because they
often interact with several low-affinity targets rather than block-
ing a single high-affinity target, ultimately limiting co-evolution of
HDPs and bacterial resistance (Peschel and Sahl, 2006). This is
supported by the present results because assessment of resis-
tance development demonstrated that both polymyxin B and
HDM-4 remained highly active against E. coli after continuous
treatment with subinhibitory concentrations, in contrast to all
tested conventional antibiotics. Still, bacterial resistance toward
HDPs has been observed previously due to several defense stra-
tegies including altered membrane composition, active efflux,
and enzymatic degradation. In the latter case, it has been shown
that the human cathelicidin LL-37 is inactivated via proteolytic
degradation by S. aureus (Sieprawska-Lupa et al., 2004). The
peptidomimetic structure of HDM-4 is not recognized by proteo-
lytic enzymes providing HDM-4 with an advantage as compared
to HDPs composed exclusively of a-amino acids, both with
respect to resistance and stability in the face of host proteases
that abound during infections.1290 Chemistry & Biology 20, 1286–1295, October 24, 2013 ª2013 EImportantly, evidence suggests that HDPs generally exert their
natural anti-infective functions mainly through immune modula-
tion (Bowdish et al., 2005). Not surprisingly, this is an advantage
in the context of resistance development as such an indirect
activity relieves selection pressure. It could be argued that a po-
tential anti-infective drug candidate with multiple mechanisms
including direct (i.e., bacterial killing) and indirect (i.e., immune
modulation) killing has a higher potential for success in the clinic
with reduced resistance development when compared to single-
mechanism antibiotics. In the present in vitro investigation, it was
demonstrated that HDM-4 constitutes one such candidate.
One way for bacteria to adapt to inhospitable environments
involves biofilm formation, which is a microbiological process
that is associated with 65% of all human infections and is
linked to increased pathogenesis andmultidrug resistance (Cos-
terton et al., 1999; Donlan, 2001; Parsek and Singh, 2003). Bio-
films are highly abundant in certain infectious diseases, e.g., P.
aeruginosa biofilms in the lungs of patients with cystic fibrosis
(Ro¨mling and Balsalobre, 2012; Singh et al., 2000). As previously
described, peptoids and peptide-peptoid hybrids may be effi-
cient agents in the treatment of both Gram-negative and
Gram-positive biofilms (Kapoor et al., 2011; Liu et al., 2013).
HDM-4 exhibits broad-spectrum inhibitory activity against bio-
film formation of Gram-negative bacteria at sub-MIC levels,
thus expanding its potential applications. Notably, HDM-4
exhibited strong anti-biofilm activity at the same concentration
(8 mg/ml) toward four separate Gram-negative bacteria, suggest-
ing that the underlying mode of action against biofilms involves
different mechanisms than does the killing of planktonic cells,
as also concluded for cationic anti-biofilm peptides (de la
Fuente-Nu´n˜ez et al., 2012).
It is surprising that the structure of HDM-4, comprising only
two different residues, confers properties similar to those ex-
hibited by complex peptide sequences found in Nature. This
simple template is desirable because it should reduce the
cost-of-goods during large-scale synthesis. Indeed a feasible
gram-scale synthesis route for peptoids has been demonstrated
(Jahnsen et al., 2012).
SIGNIFICANCE
In an era in which novel antibiotic agents are greatly needed,
we have characterized the activity of a host defense pepti-
domimetic (HDM-4) with an attractive activity profile
including beneficial features such as simplicity of sequence
and proteolytic stability. We have demonstrated that HDM-4
mobilizes innate immune defenses and suppresses LPS-
mediated inflammation, thus reducing the risk of lethal
sepsis-related inflammation while maintaining potential
protective efficacy. In addition, we have shown that the
compound directly fights Gram-negative bacteria in a multi-
functional manner and that bacterial killing takes place
because of the combined effects of membrane perturbation
and targeting of intracellular components. Furthermore, we
have provided evidence that this complex mode of action is
less likely to confer resistance development in E. coli when
compared to the major classes of antibiotics currently
used in the clinic, and that activity against multiresistant
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Figure 4. Anti-Biofilm Activity
(A) Inhibition of biofilm formation by various Gram-negative bacteria. The planktonic cell MIC in the biofilm media is given for each strain in the respective panel.
The bars represent the percentage of the biomass after 24 hr of treatment with HDM-4 at different concentrations as compared to an untreated biofilm. Data are
represented as mean ± SEM.
(B) Antibiofilm activity of HDM-4 investigated by flow cell analysis ofP. aeruginosa (PA14). Biofilmwas grown in flow cells for 144 hr with continuous treatment with
8 mg/ml (i.e., 0.1253MIC) HDM-4 prior to live/dead staining (Syto-9 for green-staining of all cells and propidium iodide for red-staining of dead cells) followed by
imaging by confocal laser-scanning microscopy (CLSM) and cryo scanning-electron microscopy. For CLSM micrographs, the scale bars represent 30 mm, and
the central pictures show horizontal optical sections, while the flanking pictures show vertical optical sections.
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included resistance, toxicity, stability, and cost. HDM-4 pro-
vides advantageous properties for each of these criteria and
consequently, has high potential as a future anti-infective
drug candidate.
EXPERIMENTAL PROCEDURES
Synthesis of HDM-4 and Its Tagged Variant
HDM-4 was prepared by automated MW-assisted solid-phase peptide
synthesis on a CEM Liberty microwave peptide synthesizer as previously
described (Jahnsen et al., 2012). The fluorescent tag was introduced prior to
cleavage from the solid phase. Tagging conditions involved the use of 5
equivalents of 5(6)-carboxy-tetramethylrhodamine (Merck), 5 equivalents of
diisopropyl carbodiimide (Iris Biotech), and 5 equivalents of 1-hydroxy-7-
aza-benzotriazole (TCI) in the solvent DMF (VWR), with treatment at room tem-
perature, overnight.
Bacterial Strains
Several Gram-negative bacteria were included in the evaluation of the antibac-
terial activity of HDM-4 including E. coliO157:H7, DC2 (Clark, 1984) and DH5a
(Haney et al., 2013), P. aeruginosa PA14 (Liberati et al., 2006), S. enterica ssp
Typhimurium 14028S (Fields et al., 1989), multidrug-resistant A. baumannii
Sentry C8 (Arroyo et al., 2011), and K. pneumoniae ATCC 13883.Chemistry & Biology 20, 1286–1Antimicrobial Activity
MICs were determined using the broth microdilution method as previously
described (Jahnsen et al., 2012), with minor modifications. In brief, fresh over-
night colonies were diluted 1:500 in Mueller Hinton (MH) broth II (Difco). An
aliquot (100 ml) of bacterial suspension was added to the wells of a polypro-
pylene microtiter tray (Costar) containing 11 ml of a 10-fold concentration of
the desired test compound in 2-fold serial dilutions. The trays were incubated
at 37C for 24 hr. The MIC was determined as the lowest concentration
showing no visible growth. All measurements were carried out three times
independently in triplicate.
Killing Kinetics
The killing kinetics of E. coli O157:H7 by HDM-4 at various concentrations
were investigated, and at 43MICHDM-4was compared to imipenem (Merck),
cefotaxime (Sigma), ciprofloxacin (Sigma), and polymyxin B (Sigma). Cultures
were allowed to grow to exponential phase (optical density 600 [OD600] of
0.5), and were then diluted to 3.5–5.5 3 106 CFU/ml in MH broth II, chal-
lenged with test compound, and incubated at 37C. Residual colony counts
were determined after 0.5, 1, 2, 3, and 6 hr by plating for single colonies on
MH broth II agar. All measurements were carried out in triplicate.
Outer Membrane Depolarization
The effect of HDM-4 on the permeability of the outer membrane in E. coli
O157:H7 was evaluated by the NPN-assay (Hancock et al., 1991; Hancock295, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1291
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Figure 5. Immunomodulatory Activity of HDM-4
(A) Immunomodulatory activity of HDM-4 as compared to the strongly immunomodulatory peptide IDR-1018. The bars demonstrate the induction of
various neutrophil and monocyte chemoattractants in human PBMCs over 24 hr during treatment with two different concentrations. Data are represented as
mean ± SEM.
(B) Anti-endotoxin activity of HDM-4 as compared to that of IDR-1018. Human PBMCs were treated with two different concentrations of the compounds prior to
addition of 10 ng/ml P. aeruginosa LPS. The activity was measured as the reduced secretion of two pro-inflammatory cytokines over 24 hr. Data are represented
as mean ± SEM.
(C) LPS-binding activity as measured by the displacement of Oregon Green-tagged polymyxin B from LPS. Data are represented as mean ± SEM.
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amine (NPN) into the bacterial cytoplasmic membrane. The experiment was
performed three times.
Inner Membrane Depolarization
Depolarization of the inner membrane was investigated by the diSC3-5 (Molec-
ular Probes) assay as previously described (Wu et al., 1999) and later modified
(Chongsiriwatana and Barron, 2010). All measurements of the increase in
diSC3-5 fluorescence as an assessment of membrane depolarization were
carried out three times.
Imaging of Membrane Damage
Membrane damage on E. coli O157:H7 exerted by HDM-4 was demonstrated
with field emission scanning-electron microscopy. Bacterial cultures were
grown to the exponential phase, and were then diluted to 2-5 3 107 CFU/ml
in MH broth II as determined by plate counting. The bacteria were pelleted
and resuspended in 0.1M sodium cacodylate (Fluka) buffer (pH 7.4) containing
the test compound. The bacteria were treated for 30 min at 23C prior to fixa-
tion with 2.5% glutaraldehyde for 1 hr. Subsequently, the cells were loaded
onto a 0.2 mm membrane filter (Whatman Nuclopore Track) using a syringe.
The cells were washed with cacodylate buffer, and were then contrasted
with 1% osmium tetroxide. The cells were washed with water and dehydrated
by using ethanol and nitrogen critical point drying. The specimens were
mounted onto stubs with Pelco conductive silver glue and coated with 5 nm
gold/palladium using a sputter coater. The images were obtained on a Hitachi
S4700 SEM operated at 5 kV and 10 mA at 5.0 mm working distance.
Imaging of Treated E. coli by Confocal Laser Scanning Microscopy
Localization of HDM-4 in E. coli (O157:H7) cells was investigated with TAMRA-
tagged HDM-4 using confocal laser-scanning microscopy. Bacterial cultures
were grown in MH broth II to reach exponential phase, and were then diluted1292 Chemistry & Biology 20, 1286–1295, October 24, 2013 ª2013 Eto 3.933 107 CFU/ml as determined by plate counting. The cells were pelleted
and resuspended in 5 mM PBS buffer (as tablets from Sigma: 0.01 M phos-
phate, 2.7 mM KCl, 0.137 M NaCl, and pH 7.4) containing the test compound.
The bacteria were treated for 30 min at 37C in the dark prior to fixation with
2.5% glutaraldehyde (Alfa Aesar) for 1 hr at 23C in the dark. The cells were
washed twice with PBS buffer, pelleted, and resuspended in PBS buffer con-
taining 10 mg/ml DAPI. The cells were rested for 1 hr at 23C in the dark. A drop
of the bacterial suspension was placed on a coverslip, and imaging of the
specimen was carried out with a Zeiss LSM 780 inverted confocal laser-scan-
ning microscopy equipped with lasers for DAPI excitation at 405 nm and
TAMRA at 543 nm. Image processing was carried out by using Fiji ImageJ
1.47q. Blue DAPI was falsely colored green and red TAMRA was falsely
colored magenta.
DNA Binding Assay
Binding of HDM-4 to plasmid DNA was investigated by using an agarose gel-
retardation assay for evaluation of antimicrobial peptide binding to DNA as
previously described (Haney et al., 2013) with modifications. Unmodified
pUCP19 plasmid was purified from an overnight culture of E. coli (DH5a/
pUCP19) cells using a Plasmid Purification Kit (QIAGEN Inc.). Water was
used to elute the pUCP19 vector, and the concentration of the purified
plasmid was determined by using a NanoDrop machine (NanoDrop Prod-
ucts). Plasmid (200 ng) was incubated at 23C with increasing amounts of
HDM-4 in 20 ml of binding buffer (5% glycerol, 10 mM Tris–HCl at pH 8.0,
1 mM EDTA, 1 mM dithioreitol, 20 mM KCl, and 50 mg/ml BSA). After 1 hr
of incubation, 2 ml of 103 loading buffer (Invitrogen) was added to the mixture.
Half of this sample (i.e., 100 ng of plasmid) was loaded onto a 1% agarose gel
in Tris-acetate-EDTA (TAE) buffer containing SYBR Safe DNA gel stain
(Invitrogen). The gel was run at 100 V for approximately 45 min and the
DNA bands were depicted with UV light using a Chemigenius 2 Bio Imaging
System (Syngene).lsevier Ltd All rights reserved
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Sublethal treatment of E. coli O157:H7 with HDM-4, imipenem, cefotaxime,
ciprofloxacin, and polymyxin B was carried out as follows: initially, bacteria
from the same subculture were plated and treated with test compound as
for regular MIC determination. The following day, OD600 was measured.
From the well with the lowest concentration where >50% loss of OD600 could
be detected, bacteria were diluted 1:20 and plated anew. This step was
repeated until the bacteria were exposed to a total of 20 sublethal treatments.
Bacteria without treatment were plated in parallel. After 20 cycles, MIC was
determined as described, and data for treated subcultures were compared
to the nontreated subculture. The treated subcultures were grown in test tubes
for two cycles, and then MIC comparison was repeated. All MIC determina-
tions were carried out in three independent determinations.
Isolation of Peripheral Blood Mononuclear Cells
Blood from healthy adult volunteers was collected (upon informed consent) in
sodium heparin anticoagulant collection tubes (BD Biosciences), in accor-
dance with University of British Columbia ethics permission and guidelines.
The blood was diluted 1:1 with PBS buffer, pH 7. Blood cells were separated
over Ficoll-Paque (GE Healthcare) by centrifugation (Beckman Coulter Allegra
6R) for 20min at 1,450 rpm. The PBMCswere collected andwashed twice with
PBS. The cells were then resuspended in complete RPMI 1640 medium
(Hyclone) supplemented with 10% FBS (Invitrogen) and quantified for viable
cells by Trypan blue (Sigma) exclusion on a Zeiss light microscope.
Treatment of PBMCs
PBMCs were diluted to 13 106 cells/ml in RPMI 1640 medium supplemented
with 10% FBS and seeded into a 48-well plate (Costar) with 500 ml in each well.
The cells were then left in the incubator for 2 hr at 37C in 5% CO2. The cells
were then treated with HDM-4 or IDR-1018 at both 20 mg/ml and 50 mg/ml. As a
negative control, 2% Triton X-100 was used. In experiments aimed at deter-
mining the LPS-neutralizing effect of HDM-4, Pseudomonas aeruginosa strain
H103 LPS was added to give a final concentration of 10 ng/ml. After 24 hr of
exposure at 37C in 5% CO2, the content of each well was transferred to an
Eppendorf tube, and then the cells were pelleted (Thermo Electron Legend
Micro 21) at 2,000 rpm for 10min. The supernatants were aliquoted and stored
at 20C before cytokine or LDH determinations. All treatments were carried
out twice.
LDH Assay
Peptide toxicity against PBMCs was assessed by determining the release of
LDH into the supernatant upon treatment, as previously described (Decker
and Lohmann-Matthes, 1988). The assay was carried out five times in
duplicate.
ELISA
The levels of various chemokines comprising IL-8, MCP-1, and MCP-3 as well
as the pro-inflammatory cytokines IL-6 and TNF-a were detected by using a
sandwich ELISA method and eBiosciences kits (Invitrogen, R&D Systems).
All ELISAs were carried out in duplicate on at least five biological replicates.
LPS Binding
LPS binding was investigated byOregon Green-tagged polymyxin fluorophore
displacement as previously described (Moore et al., 1986) using 4 mg Pseudo-
monas aeruginosa PAO1 strain H103 LPS. Polymyxin B was used as a positive
control while buffer was used as a negative control. All titrations were carried
out three times.
Inhibition of Biofilm Formation
Screening for antibiofilm activity was performed in a microtiter plate assay as
previously described (Pitts et al., 2003) with minor modifications (de la Fuente-
Nu´n˜ez et al., 2012). In brief, fresh overnight cultures were diluted in the
following manner: E. coli 1:100 in Lennox broth (LB; Fisher Scientific): P. aer-
uginosa 1:100 in LB,S. typhimurium 1:10 in BM2 glucosemedium—62mMpo-
tassium phosphate buffer (pH 7), 7 mM (NH4)2SO4, 2 mM MgSO4, 10 mM
FeSO4, 0.4% (wt/vol) glucose, and 0.5% casamino acids (BDH, Fisher and
Sigma)—andA. baumannii 1:10 in LB (Difco). An aliquot (100 ml) of this bacterial
suspension was added to the wells of a polypropylene microtiter plate (Costar)Chemistry & Biology 20, 1286–1containing 11 ml of ten times the desired final concentration of test compound
in 2-fold serial dilutions. After incubation at 37C for 24 hr, adherent biofilmwas
determined by the crystal violet staining method. The experiment was carried
out in triplicate.
Flow Cell Experiments and Biofilm Imaging by Confocal and Cryo-
Scanning-Electron Microscopy
The flow cell cultivation was carried out as previously described (de la Fuente-
Nu´n˜ez et al., 2012) with modifications. In brief, fresh overnight cultures of P.
aeruginosa PA14 were diluted to 1.5–7.5 3 108 CFU/ml in LB as determined
by plate counts. Then 400 ml of bacterial suspension was injected into each
channel of a three-channel flow cell (IBI scientific), and subsequently the cells
were allowed to adhere for 2 hr. A continuous flow of BM2 medium with or
without 8 mg/ml HDM-4 at 3.6 ml/hr was applied to the channels, and the bio-
filmwas grown for 144 hr with a setup consisting of Pharmacia LBK pumps and
sterilized silicon tubing (VWR). After cultivation, the biofilm was stained with
1 mM Syto-9 (Invitrogen) and 5 mM propidium iodide (Invitrogen) in 0.9%
NaCl. Imaging was carried out on an Olympus FV-1000 inverted confocal
laser-scanning microscope equipped with lasers for green Syto-9 excitation
at 488 nm and red propidium iodide excitation at 568 nm. Three-dimensional
reconstruction was carried out in Imaris Bitplane software.
After undergoing confocal microscopy, the specimen was fixed with 2.5%
glutaraldehyde and depicted with CryoSEM. Small pieces of each flow cell
coverslip were excised with a diamond cutter, mounted onto a stub, and
plunge-frozen in liquid nitrogen. The stub was transferred to continuous
vacuum conditions in a CryoSEM sample preparation container (Emitech
K1250). The temperature was increased to 95C and decreased to
138C through a 20 min time span to sublimate any condensed water. The
sample was coated with 5 nm platinum and transferred to a Hitachi S4700
SEM operated at 5 kV and 10 mA at 12.5–15.0 mm working distance with a
30% specimen tilt.
Statistical Analysis
Statistical analyses were carried out using Graphpad Prism 5 software. All
standard curves had R squared values of >0.95 and at least five data points.
Data sets were compared with Student’s t test for paired data sets and
ANOVA for multiple data sets. All data described as significant had at least a
95% confidence interval: *p% 0.5. ****p% 0.0001.
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